Combination of RUNX1 Inhibitor and Gemcitabine Mitigates Chemo-Resistance in Pancreatic Ductal Adenocarcinoma by Modulating BiP/PERK/eIF2α-Axis-Mediated Endoplasmic Reticulum Stress

Scientists constructed the stably expressing cell lines with shRUNX1 and RUNX1, and successfully established Gemcitabine (GEM)-resistant cell line. The role of RUNX1 in GEM resistance was determined by CCK8 assay, plate colony formation assay and apoptosis analysis in vitro and in vivo.